Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Long-Term Deferred Tax (2022 - 2023)

Historic Long-Term Deferred Tax for Syndax Pharmaceuticals (SNDX) over the last 2 years, with Q4 2023 value amounting to $79.6 million.

  • Syndax Pharmaceuticals' Long-Term Deferred Tax rose 6278.12% to $79.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was $79.6 million, marking a year-over-year increase of 6278.12%. This contributed to the annual value of $79.6 million for FY2023, which is 6278.12% up from last year.
  • Latest data reveals that Syndax Pharmaceuticals reported Long-Term Deferred Tax of $79.6 million as of Q4 2023, which was up 6278.12% from $48.9 million recorded in Q4 2022.
  • In the past 5 years, Syndax Pharmaceuticals' Long-Term Deferred Tax registered a high of $79.6 million during Q4 2023, and its lowest value of $48.9 million during Q4 2022.